Biogen, Eisai Alzheimer Treatment Shows Positive Signs in Advanced Trial
12 11월 2021 - 8:40AM
Dow Jones News
By Kimberly Chin
Biogen Inc. and Eisai Co. said that a Phase 3 trial of its
Alzheimer treatment yielded some positive results, including the
reduction of tau pathology.
The companies said that the Aduhelm treatment, a monoclonal
antibody that is directed against amyloid beta, was able to lower
plasma p-tau181, a biomarker of the tau tangles found in those with
Alzheimer's disease, in advanced trials in both a dose- and
time-dependent setting.
The companies said the reduction in plasma p-tau181 was
significantly correlated with less cognitive and functional decline
from the disease. The plasma p-tau181 reduction was also correlated
with the lowering of amyloid beta plaque.
Amyloid beta plaque and neurofibrillary tangles, which are made
up of abnormal p-tau, are considered the hallmarks of Alzheimer's
disease and can disrupt the communication between neurons, leading
to the brain's decline.
Biogen and Eisai looked at data from about 7,000 plasma samples
from over 1,800 patients in the trials. It presented its findings
at the Clinical Trials on Alzheimer's Disease conference on
Thursday.
Biogen's shares rose 2.4% after hours to $273.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
November 11, 2021 18:25 ET (23:25 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eisai (PK) (USOTC:ESALY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Eisai (PK) (USOTC:ESALY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Eisai Company Ltd (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Eisai Company Ltd (PK) News Articles